ArticleBlood neoplasia2026

Immunologic changes during treatment with romidepsin, azacitidine, and lenalidomide in relapse/refractory T-cell lymphoma.

Max J Gordon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.